December 23, 2025 08:49 am (IST)

Make this your homepage

All Finance

Bangladesh on edge: Student leader shot as pre-poll violence deepens after Hadi killing | Historic deal sealed: India, New Zealand sign landmark Free Trade Agreement in record time | Supreme court snubs urgent plea to stop PMO’s chadar offering at Ajmer Sharif | Emergency landing drama: Air India flight heads back to Delhi after engine malfunction! | PM Modi slams ‘cut and commission’ TMC in virtual Taherpur address | US launches Operation Hawkeye Strike in Syria targeting ISIS after Americans killed | Horror on tracks: Rajdhani Express ploughs into elephant herd, eight killed in Assam | Horror in Bangladesh: Hindu man lynched and set on fire amid violent protests | Bangladesh in flames: Student leader Sharif Osman Hadi's death triggers massive protests, media offices torched | Chaos in Dhaka! Protesters assault New Age Editor, burn down newspaper offices amid deadly unrest

Dr Reddy's acquires rights to an investigational anti-cancer agent

India blooms News Service | | Mar 31, 2016, at 07:47 pm

#Raghav Chari # Executive Vice President # Proprietary Products Group # Dr Reddy

Hyderabad, Mar 31 (IBNS) Dr Reddy's Laboratories, an integrated pharmaceutical company, announced on Thursday that it has entered into a licensing agreement with Eisai Company Limited of Japan, by which Dr Reddy's will be granted exclusive worldwide development and commercialization rights (excluding Japan and Asia) for Eisai's investigational anticancer agent E7777.

Eisai will develop and market E7777 in Japan and Asia; Dr Reddy's holds the option for rights to develop and market the agent in India, the company said.

In exchange of these rights, Eisai will receive milestone payments in line with obtaining marketing approval and the achievement of agreed upon sales targets.

Raghav Chari, Executive Vice President, Proprietary Products Group, Dr Reddy's Laboratories, said, "E7777 has significant potential as an important component of systemic therapy for cutaneous T-cell lymphoma (CTCL). This therapy represents an extension of our current efforts in the dermatology space to an important segment of skin-related cancers."

Support Our Journalism

We cannot do without you.. your contribution supports unbiased journalism

IBNS is not driven by any ism- not wokeism, not racism, not skewed secularism, not hyper right-wing or left liberal ideals, nor by any hardline religious beliefs or hyper nationalism. We want to serve you good old objective news, as they are. We do not judge or preach. We let people decide for themselves. We only try to present factual and well-sourced news.

Support objective journalism for a small contribution.

India
International

Related Images

Nirmala Sitharaman presents Budget 2025 Feb 01, 2025, at 03:41 pm

Veedol signs former Indian skipper Sourav Ganguly as brand ambassador Jun 29, 2024, at 06:38 am

In Images: Glimpses from Bengali film Fatafati's premiere May 13, 2023, at 08:39 pm